HALO Quote, Financials, Valuation and Earnings

Johnson & Johnson has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 50.24%. Halozyme Therapeutics's return on equity of 137.42% beat Johnson & Johnson's return on equity of 30.18%.

Halozyme Therapeutics has a consensus price target of $67.00, signalling upside risk potential of 22.85%. On the other hand Johnson & Johnson has an analysts' consensus of $169.18 which suggests that it could grow by 10.62%. Given that Halozyme Therapeutics has higher upside potential than Johnson & Johnson, analysts believe Halozyme Therapeutics is more attractive than Johnson & Johnson.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.425, suggesting its less volatile than the S&P 500 by 57.471%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.24% to investors and pays a quarterly dividend of $1.24 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. Halozyme Therapeutics's net income of $118.1M is lower than Johnson & Johnson's net income of $11B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 14.51x while Johnson & Johnson's PE ratio is 17.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.48x versus 4.15x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 32.71%. Halozyme Therapeutics's return on equity of 137.42% beat Merck &'s return on equity of 39.02%.

Halozyme Therapeutics has a consensus price target of $67.00, signalling upside risk potential of 22.85%. On the other hand Merck & has an analysts' consensus of $101.91 which suggests that it could grow by 31.36%. Given that Merck & has higher upside potential than Halozyme Therapeutics, analysts believe Merck & is more attractive than Halozyme Therapeutics.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Merck & has a beta of 0.429, suggesting its less volatile than the S&P 500 by 57.139%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Merck & offers a yield of 4.07% to investors and pays a quarterly dividend of $0.81 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Merck &'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Merck & quarterly revenues of $15.5B. Halozyme Therapeutics's net income of $118.1M is lower than Merck &'s net income of $5.1B. Notably, Halozyme Therapeutics's price-to-earnings ratio is 14.51x while Merck &'s PE ratio is 11.29x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.48x versus 3.08x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 6.22%. Halozyme Therapeutics's return on equity of 137.42% beat Insulet's return on equity of 36.9%.

Halozyme Therapeutics has a consensus price target of $67.00, signalling upside risk potential of 22.85%. On the other hand Insulet has an analysts' consensus of $328.73 which suggests that it could grow by 2.29%. Given that Halozyme Therapeutics has higher upside potential than Insulet, analysts believe Halozyme Therapeutics is more attractive than Insulet.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Insulet quarterly revenues of $569M. Halozyme Therapeutics's net income of $118.1M is higher than Insulet's net income of $35.4M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 14.51x while Insulet's PE ratio is 57.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.48x versus 10.81x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.

Steris PLC has a net margin of 44.59% compared to Halozyme Therapeutics's net margin of 9.84%. Halozyme Therapeutics's return on equity of 137.42% beat Steris PLC's return on equity of 9.5%.

Halozyme Therapeutics has a consensus price target of $67.00, signalling upside risk potential of 22.85%. On the other hand Steris PLC has an analysts' consensus of $263.11 which suggests that it could grow by 8.28%. Given that Halozyme Therapeutics has higher upside potential than Steris PLC, analysts believe Halozyme Therapeutics is more attractive than Steris PLC.

Halozyme Therapeutics has a beta of 1.256, which suggesting that the stock is 25.56% more volatile than S&P 500. In comparison Steris PLC has a beta of 0.956, suggesting its less volatile than the S&P 500 by 4.397%.

Halozyme Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Steris PLC offers a yield of 0.92% to investors and pays a quarterly dividend of $0.57 per share. Halozyme Therapeutics pays -- of its earnings as a dividend. Steris PLC pays out 35.77% of its earnings as a dividend. Steris PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Halozyme Therapeutics quarterly revenues are $264.9M, which are smaller than Steris PLC quarterly revenues of $1.5B. Halozyme Therapeutics's net income of $118.1M is lower than Steris PLC's net income of $145.7M. Notably, Halozyme Therapeutics's price-to-earnings ratio is 14.51x while Steris PLC's PE ratio is 39.19x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Halozyme Therapeutics is 6.48x versus 4.41x for Steris PLC. Usually stocks with elevated PS ratios are considered overvalued.